Navigation Links
ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference
Date:5/4/2010

rop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='92776124';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.chemocentryx.com/">www.chemocentryx.com.

Any statements in this press release about ChemoCentryx's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as may, believe, will, expect, anticipate, estimate, intend, predict, seek, potential, continue, plan, should, could and would or the negative of these terms or other comparable terminology. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to (i) the initiation, timing, progress and results of ChemoCentryx's preclinical studies and clinical trials, (ii) ChemoCentryx's ability to advance product candidates into clinical trials, (iii) GSK's exercise of its license options, (iv) the commercialization of ChemoCentryx's product candidates, (v) the implementation of ChemoCentryx's business model, strategic plans for its business, product candidates and technology, (vi) ChemoCentryx's ability to maintain and establish collaborations or obtain additional government grant funding, (vii) ChemoCentryx's estimates of its expenses, future revenues, capital requirements and its needs for additional financing, (viii) the timing or likelihood of regulatory filings and approvals, (ix) the
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Spherix Reports Second Quarter Earnings
10. Tapestry Reports Second Quarter 2007 Results
11. Callisto Reports on Second-Quarter 2007 Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015   Synageva BioPharma ... a biopharmaceutical company developing therapeutic products for rare ... (NORD™), the European Organisation for Rare Diseases™ (EURORDIS™), ... world in observing Rare Disease Day. ... patient organizations, industry, and other participants conduct special ...
(Date:2/27/2015)...  Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), ... 3D bioprinting technology, announced today that Keith ... present live at VirtualInvestorConferences.com on March 5th. ... for this Company update," said Mr. Murphy. "We ... of the exVive3D Liver, Bioprinted Human Tissue, commercialization ...
(Date:2/27/2015)... and JERUSALEM , Feb. ... company developing octreotide capsules, its lead product for the ... $70 million Series E financing round. Participants in the ... Ventures, and an undisclosed blue chip public investment fund, ... 7 Med Health Ventures, Abingworth and ARCH Venture Partners. ...
Breaking Medicine Technology:Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
(Date:3/1/2015)... 2015 Theme and plugin developers from ... pack for Final Cut Pro X entitled Transccordion. ... to any FCPX editors project.” Said Christiana Austin, CEO ... tools needed to easily drag and drop their accordion ... many different controls over the parameters of this transition ...
(Date:2/28/2015)... 01, 2015 Heart diseases are on ... percent of urban adult population and 5 percent of ... diseases and 20-30 percent of them require specialized investigation ... and coronary vascular diseases (CVD). , A division of ... market research report titled “Indian Coronary Stent Market Forecast ...
(Date:2/28/2015)... 28, 2015 The Heart Fit Clinic ... distributor of the machine. The Heart Fit Clinic is ... like a franchise model. The goal is to scale ... heart disease. To buy External Counterpulsation machines ... help individuals through this process and achieve the desired ...
(Date:2/28/2015)... Vancouver personal injury lawyers at Jiwa Law ... by time limits. They stated that in many cases, missing ... even nullify it. Many a time, delays in making an ... under BC law. As a result, experts at Jiwa Law ... consult a personal injury lawyer in order to know more ...
(Date:2/28/2015)... 2015 The Mesothelioma Applied Research ... at the International Symposium on Malignant Mesothelioma on Monday, ... the Hyatt Regency Bethesda in Bethesda, Maryland. The following ... and commitment to the mission to cure mesothelioma. , ... be presented to Miriam Ratner. Miriam runs the Meso ...
Breaking Medicine News(10 mins):Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4
... Cow Disease, also known as Bovine Spongiform Encephalopathy (BSE), affects ... control and the animal ultimately dies. Prion proteins are believed ... may contain these prion proteins and the disease might be ... drink its milk, according to a new study. ...
... has indicated the benefits of tomato and broccoli in the ... both the vegetables, are a great blessing in the reduction ... isolation. ,It is estimated that one out ... making it the most notorious of male cancers. Annually, 32,000 ...
... ‘present’ - the common cause of amnesia, also prevents victims ... in the present. ,Researchers, reporting their study ... Sciences at the Wellcome Trust Centre for Neuroimaging, University College ... the brain that is crucial in learning and memory. ...
... federal scanner, which has pointed out a 4% decline in ... Department of Health and Human Service has attributed this drop ... 1996 to 2003- to the spiraling growth in expenditures on ... ,The Agency for Healthcare Research and Quality in Health ...
... melanoma screening of adults age 50 or older appears ... screening programs, according to an article in the January ... only cancer for which incidence and death rates continue ... to be underused, according to background information in the ...
... may come true; for fat people and inventors. ,Scientists ... those of Britain are no exception. //Currently, two thirds of the ... has decided to put a morbidly obese figure of 2.2 million ... Imperial College London. ,Bloom’s quest is to create a chewing ...
Cached Medicine News:Health News:Tomato and Broccoli Combo may Help Fight Prostate Cancer 2Health News:Amnesia Halts Future Thinking: Study 2Health News:One-time Melanoma Screening Appears to Be Cost-effective for Elderly People 2Health News:Chew That Fat Away 2
Front protection with choice of adjustable 2" buckle or velcro belt which crosses the back for a comfortable fit. Adjustable straps at shoulders keeps apron snug....
... peripheral nerve stimulator automatically ... nerve locator or a ... upon which patient lead ... NSL-5 electrode lead set, ...
Low pressure automatic tourniquet with manual time. Includes extension hose and spiral replacement hose....
... Tupper's Universal Hand Holder and Retractor ... the hand in any position needed. ... skin or tendon hooks, fixate the ... With the patient's hand held firmly, ...
Medicine Products: